OCX Insider Trading Activity and SEC Form 4 Filings
OCX insider trading summary
No open-market insider purchases or sales of Oncocyte Corp (OCX) have been reported on SEC Form 4 in the past 12 months.
Latest OCX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 7, 2025 | Andrea S. James | Chief Financial Officer | Buy | $200K (97,561 @ $2.05) |
| Feb 7, 2025 | Patrick W Smith | 10% Owner | Buy | $2.2M (1,077,600 @ $2.05) |
| Feb 6, 2025 | Broadwood Capital Inc | 10% Owner | Buy | $9.2M (4,505,488 @ $2.05) |
| Feb 6, 2025 | Broadwood Partners, L.P. | 10% Owner | Buy | $0 (0 @ $0.00) |
| Feb 6, 2025 | Neal C Bradsher | 10% Owner | Buy | $9.2M (4,505,488 @ $2.05) |
| Feb 6, 2025 | Neal C Bradsher | 10% Owner | Buy | $0 (0 @ $0.00) |
| Feb 6, 2025 | Broadwood Partners, L.P. | 10% Owner | Buy | $9.2M (4,505,488 @ $2.05) |
| Feb 6, 2025 | Broadwood Capital Inc | 10% Owner | Buy | $1.4M (660,207 @ $2.05) |
| Feb 6, 2025 | Broadwood Partners, L.P. | 10% Owner | Buy | $1.4M (660,207 @ $2.05) |
| Feb 6, 2025 | Neal C Bradsher | 10% Owner | Buy | $1.4M (660,207 @ $2.05) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.